

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket No. 0575/52876/JPW/ALB	Serial No. 08/905,709
	Applicant David Stern and Ann Marie Schmidt	
	Filing Date August 5, 1997	Group 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
ew	US	5 8 6 4 0 1 8	4/16/96	Morser, et al.			
	US	5 6 8 8 6 5 3	11/18/97	Ulrich, et al.			
	US	5 5 6 5 3 4 4	6/27/96	Vlassara, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
ew	WO	9 7 3 9 1 2 5	10/23/98	PCT				
	WO	9 7 3 9 1 2 1	10/23/97	PCT				
	WO	9 7 2 6 9 1 3	6/31/97	PCT				
	WO	9 8 2 2 1 3 8	5/28/98	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ew	Brett, J. et al.,(1993) Survey of the distribution of a newly-characterized receptor for AGEs in tissues. Am. J. Pathol. 143:1699-1712;
	Connolly ES, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ, (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurg. 38:523-532;
	Gibbons GH and Dzau VJ,(1996) Molecular therapies for vascular diseases. Science. 272:689-693;

EXAMINER <i>Elaine Laraw-Wesley</i>	DATE CONSIDERED <i>4/16/02</i>
-------------------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Applicants: David M. Stern, et al.,
 Serial No.: 08/905,709
 Filing Date: August 5, 1997
Exhibit A



RECEIVED

Page 2 of 4

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

MAR 15 2002

Atty. Docket No.
0575/52876/JPW/ALB
Applicant
TECH CENTER 1800/2900Serial No.
08/905,709

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

David Stern and Ann Marie Schmidt

Filing Date
August 5, 1997Group
1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ew
Hori et al., (1997) The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol. In: The Endothelium in Clinical Practice. Chapter 11, pages 311-329;

Khoury, J., et al., (1994) "Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors." J. Biol.Chem., 269:10197-10200;

Kindy, S. Mark and Rader, J. Daniel (1998) "Reduction in Amyloid A Amyloid Formation in Apolipoprotein-E-Deficient Mice," *American Journal of Pathology* 152: 1387-1395;

Marui, N., et al. (1993) "VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells" *J. Clin. Invest.*, 92:1866-1874;

Nakamura Y. et al.(1993) "Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus." *Am. J. Pathol.* 143(6): 1649-1656;

Nakashima Y, Plump A, Raines E, Breslow J, Ross R. (1994) "ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree." *Arterioscler. Thromb.* 141:133-140;

Neeper M. et al., (1992) "Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins." *J. Biol. Chem.* 267:14998-15004;

Palinski W. et al. (1995) "Immunological evidence for the presence of advanced glycation endproducts in atherosclerotic lesions of euglycemic rabbits. *Arterioscl. Thromb. and Vasc. Biol.* 15(5):571-582;

EXAMINER ew

DATE CONSIDERED

4/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

RECEIVED

Page 3 of 4

MAR 15 2002

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
08/202876/JPW/ALBSerial No.
08/905,709

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
David Stern and Ann Marie SchmidtFiling Date
August 5, 1997Group
1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	Park, L., et al. (1998) Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). Nature Medicine, 4:1025-1031;
	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;
	Ritthaler, et al. (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am. J. Path 146:688-694;
	Schmidt, A.M., et al. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92:2155-2168;
	Schmidt, A.M., et al. (1997) The V-Domain of Receptor for advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes. Circulation Supplement, 96:194:1-37;
	Schmidt, A.M., et al. (1994) Cellular receptors for advanced glycation end products. Arterioscler. Thromb, 14:1521-1528;
	Schmidt, A.M., et al. (1995) The Dark Side of Glucose (News and Views). Nature Medicine, 1:1002-1004;
	Schmidt, A-M, et al. (1994) Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. (USA), 91:8807-8811;
	Schmidt A-M, Yan S-D, Wautier J-L, Stern DM: Activation of RAGE: a mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84:489-497;

EXAMINER

Chare Laram-Wesley

DATE CONSIDERED

4/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

RECEIVED

Page 4 of 4

Form PTO-1449

MAR 12 2002

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

0575/52876/JPW/ALB

Serial No.

08/905,709

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

David Stern and Ann Marie Schmidt

Filing Date

August 5, 1997

Group

1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ew	Vlassara, H., et al. (1995) Identification of Galectin-3 as a high affinity binding protein for advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex. Molecular Medicine, 1:634-646;
	Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. invest. 70:138-151;
	Wautier, J.L., et al. (1996) Receptor-mediated endothelial dysfunction in diabetic vasculopathy: Srage blocks hypermeability in diabetic rats .J. Clin. Invest., 97(1): 238-243;
	Wautier, J.L., et al. (1996). Interaction of diabetic erthrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation supplement 94 (8):4139;
y	Yan, S-D., et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J.Biol.Chem., 269:9889-9897.

EXAMINER

Cherie Laran Wesley

DATE CONSIDERED

6/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.